Table 3.
Univariable associations between elafin levels at day +15 and clinical variables with stage III-IV skin acute GVHD using the Fine-Gray model.
| Variables | Skin aGVHD III-IV | |
|---|---|---|
| SHR (95% CI) | p-value | |
| Age >50 years | 0.62 (0.12–3.23) | 0.5 |
| Female sex | 1.03 (0.19–5.43) | 0.96 |
| Sorror >3 | 0.51 (0.09–2.67) | 0.4 |
| DRI Very high + high Previous HSCT |
1.14 (0.25–5.08) 1.35 (0.15–11.98) |
0.81 0.78 |
| Underlying disease other than AML |
7.86 (0.91–67.39) | 0.06 |
| Infused TNC >6 × 108/kg | 0.98 (0.19–5.06) | 0.98 |
| RIC conditioning regimen | 1.67 (0.32–8.66) | 0.5 |
| Elafin +15 ≥20,373 pg/ml | 26.5 (3.14–223.3) | 0.003* |
SHR, subdistribution hazard ratio; HSCT, hematopoietic stem cell transplantation; AML, acute myeloid leukemia; TNC, total nucleated cells; DRI, disease risk index; *Statistically significant.